By Blair Childs, senior vice president of public affairs, Premier
Premier wholeheartedly applauds the FDA’s recognition of the importance of gathering real-world evidence (RWE) to gain insight into safety, efficacy, patient outcomes and cost-effectiveness of drugs and biologicals. As an alliance committed to delivering value to our members and their patients and with one of the most comprehensive repositories of healthcare data, we see firsthand the value RWE can provide patients, providers and innovators. We also believe RWE can be used to transform the Drug Efficacy Study Implementation (DESI) pathway that, as currently designed, creates barriers to market entry leading to price gouging and shortages.
As one of the nation’s largest purveyor of RWE, with data on approximately 45 percent of patients seen in hospitals across the nation, Premier looks forward to working with the FDA to implement the Framework for FDA’s Real World Evidence Program.
About Premier, Inc.
Premier Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of approximately 4,000 U.S. hospitals and health systems and approximately 165,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. Premier plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram, and Premier’s blog for more information about the company.